BiotechTube

Sulopenem + Sulopenem-Etzadroxil/Probenecid + Ertapenem + Ciprofloxacin + Amoxicillin-clavulanate

Phase 3Completed
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Complicated Urinary Tract Infections

Conditions

Complicated Urinary Tract Infections

Trial Timeline

Sep 18, 2018 → Dec 14, 2019

NCT ID
NCT03357614

About Sulopenem + Sulopenem-Etzadroxil/Probenecid + Ertapenem + Ciprofloxacin + Amoxicillin-clavulanate

Sulopenem + Sulopenem-Etzadroxil/Probenecid + Ertapenem + Ciprofloxacin + Amoxicillin-clavulanate is a phase 3 stage product being developed by Iterum Therapeutics for Complicated Urinary Tract Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT03357614. Target conditions include Complicated Urinary Tract Infections.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT03357614Phase 3Completed

Competing Products

20 competing products in Complicated Urinary Tract Infections

See all competitors
ProductCompanyStageHype Score
ZY19489 + Ferroquine (FQ) + PlaceboZydus LifesciencesPhase 1
33
HRS-8427 + Imipenem and Cilastatin Sodium + HRS-8427 placebo + Imipenem and Cilastatin Sodium placeboJiangsu Hengrui MedicinePhase 3
77
HRS -8427 + Imipenem and Cilastatin SodiumJiangsu Hengrui MedicinePhase 2
52
Ceftolozane/Tazobactam + Metronidazole + Meropenem + PlaceboMerckPhase 3
77
Vancomycin + Daptomycin + Semi-Synthetic PenicillinMerckApproved
85
CXA-201 and metronidazole + MeropenemMerckPhase 3
77
CXA-101 + CeftazidimeMerckPhase 2
52
Ceftolozane/Tazobactam + MeropenemMerckPhase 2
52
Imipenem+Cilastatin/RelebactamMerckPhase 3
77
Daptomycin + VancomycinMerckApproved
85
CXA-101/ tazobactam and metronidazole + meropenem plus saline placeboMerckPhase 2
52
CXA-201 + LevofloxacinMerckPhase 3
77
Ceftolozane/Tazobactam + Metronidazole + Meropenem + Placebo for MetronidazoleMerckPhase 2
52
MK0826; ertapenem sodium + Comparator: ceftriaxone + metronidazoleMerckApproved
85
MK0826, /Duration of Treatment : 8 Weeks + Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 WeeksMerckPhase 3
77
KLU156 + CoartemNovartisPhase 3
77
LYS228 + Standard of care therapyNovartisPhase 2
52
Artemether-lumefantrine (COA566)NovartisPhase 2/3
65
INE963NovartisPhase 2
52
KAE609 + SoC (Coartem) + KLU156NovartisPhase 2
52

Other Products from Iterum Therapeutics

CiprofloxacinApproved
77
Sulopenem etzadroxil/probenecid + Amoxicillin/clavulanatePhase 3
69
Sulopenem-Etzadroxil/Probenecid + CiprofloxacinPhase 3
69
Ertapenem + Sulopenem-Etzadroxil/Probenecid + Ciprofloxacin + Metronidazole + Amoxicillin-Clavulanate + SulopenemPhase 3
69
Azithromycin plus hydroxychloroquinePhase 3
69